These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25583785)

  • 1. Cancer-killing CAR therapies gain speed.
    Weber M
    Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helping CAR T cells reach tumors.
    Cancer Discov; 2015 Jan; 5(1):OF6. PubMed ID: 25583818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 4. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A; Abken H
    Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract]   [Full Text] [Related]  

  • 7. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
    Hammill JA; Afsahi A; Bramson JL; Helsen CW
    Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 12. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
    Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
    Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.
    Valton J; Guyot V; Marechal A; Filhol JM; Juillerat A; Duclert A; Duchateau P; Poirot L
    Mol Ther; 2015 Sep; 23(9):1507-18. PubMed ID: 26061646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
    Davies DM; Maher J
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):165-78. PubMed ID: 20373147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
    Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fine-tuning the effects of T-cell therapy.
    Cancer Discov; 2014 Feb; 4(2):137. PubMed ID: 24501286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.